Smoking Causes the Highest Mortality Rate in the US, Accounting for
440,000 Deaths

DUBLIN, Ireland--(BUSINESS WIRE)--March 27, 2006--Research and Markets
(http://www.researchandmarkets.com/reports/c31650) has announced the
addition of Opportunities in the Pharmacotherapy of Addiction to their
offering.


Business Implications

-- Although addiction to alcohol and illicit drugs is a significant
problem that costs society hundreds of billions of dollars each year,
only a limited number of treatments are available to address this
problem. Until 2004, only two drugs (disulfiram (Odyssey
Pharmaceuticals' Antabuse) and naltrexone (Barr Pharmaceuticals'
ReVia, generics)) were approved in the United States for treatment of
alcohol dependence, and until 2002, only three drugs (methadone
(Roxane Laboratories' Dolophine, generics), naltrexone, and
levomethadyl (Roxane Laboratories' Orlaam)) were approved for
treatment of opioid dependence; levomethadyl has since been pulled
from the market.

-- The 2004 approval and 2005 market introduction of acamprosate
calcium (Forest Laboratories Campral) for treatment of alcohol
dependence and the 2002 introduction of buprenorphine and
buprenorphone/naloxone (Reckitt Benckisers Subutex and Suboxone,
respectively) for treatment of opioid dependence are representative of
changes occurring in the market for drug and alcohol addiction. We
expect that the market will continue to grow but anticipate that
expansion will be slow owing to several societal factors.

-- An estimated 46 million adults in the United States smoke
cigarettes, and smoking claims more than 440,000 lives each year.
Several products for smoking cessation are already available,
including many over-the-counter and prescription products for nicotine
replacement therapy and the antidepressant bupropion (GlaxoSmithKlines
Zyban).

-- We forecast that the U.S. market for smoking cessation will
continue to grow, fueled by the large percentage of smokers who have
expressed a desire to quit. Significant need and market opportunity
exist for a highly effective treatment, and additional non-nicotine
products for smoking cessation have reached Phase III clinical trials,
with more in earlier stages of development.

In 2003, almost 18 million people in the United States abused or were
dependent on alcohol, and almost 20 million were illicit drug users.
Many people abuse both alcohol and drugs. But the single most common
avoidable cause of morbidity and mortality in the United States,
resulting in more than 440,000 deaths and more than $75 billion in
direct medical costs each year, is smoking, according to the Centers
for Disease Control and Prevention (CDC). The CDC estimates that 46.2
million adults in the United States smoke cigarettes and that 70% of
those smokers have a desire to quit, representing a large potential
market for smoking cessation products.

In this Decision Resources report, we provide an overview of substance
abuse and dependency and review current and emerging therapies for the
treatment of addiction to alcohol, illicit drugs, and nicotine. In
conclusion, we forecast changes in the market that will increase
opportunities for companies that develop pharmacotherapeutic
treatments for addiction.

Topics Covered

Societal and Pharmacotherapy Trends in Addiction

Overview of Substance Abuse

Current Pharmacological Treatments for Addiction

Emerging Therapies for Treatment of Addiction

Prospects for Addiction Pharmacotherapy

Table 1. FDA-Approved Drugs for Treatment of Alcohol Dependence, 2005

Table 2. FDA-Approved Drugs for the Treatment of Opioid
Dependence/Addiction, 2005

Table 3. Select FDA-Approved Products for Smoking Cessation, 2005

Table 4. Emerging Pharmacological Therapies for Treatment of Alcohol
Dependence, 2005

Table 5. Early-Stage Emerging Pharmacological Therapies for the
Treatment of Drug Addiction, 2005

Table 6. Late-Stage Emerging Pharmacological Therapies for the
Treatment of Drug Addiction, 2005

Table 7. Emerging Pharmacological Therapies for Smoking Cessation, 2005

Companies Mentioned

-- Alkermes

-- Bristol-Myers Squibb

-- Catalyst Pharmaceutical Partners

-- DrugAbuse Sciences

-- GlaxoSmithKline

-- InterveXion Therapeutics

-- Nabi Biopharmaceuticals

-- Pfizer

-- Sanofi-Aventis

-- Xenova

-- Yaupon Therapeutics

For more information visit http://www.researchandmarkets.com/reports/c31650